MA29218B1 - Nonadepsipeptides acyles sous forme de derives de lysobactine - Google Patents

Nonadepsipeptides acyles sous forme de derives de lysobactine

Info

Publication number
MA29218B1
MA29218B1 MA29955A MA29955A MA29218B1 MA 29218 B1 MA29218 B1 MA 29218B1 MA 29955 A MA29955 A MA 29955A MA 29955 A MA29955 A MA 29955A MA 29218 B1 MA29218 B1 MA 29218B1
Authority
MA
Morocco
Prior art keywords
derivatives
nonadepsipeptides
acyles
lysobactin
lysobactin derivatives
Prior art date
Application number
MA29955A
Other languages
English (en)
Inventor
Nussbaum Franz Von
Nina Brunner
Rainer Endermann
Chantal Fuerstner
Elke Hartmann
Holger Paulsen
Jacques Ragot
Guido Schiffer
Joachim Schuhmacher
Niels Svenstrup
Joachim Telser
Sonja Anlauf
Michael-Alexander Bruening
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA29218B1 publication Critical patent/MA29218B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX NONADEPSIPEPTIDES (DÉRIVÉS DE LYSOBACTINE), LEURS PROCÉDÉS DE PRODUCTION AINSI QUE LEUR UTILISATION POUR PRODUIRE DES MÉDICAMENTS SERVANT AU TRAITEMENT ET/OU À LA PROPHYLAXIE DE MALADIES, NOTAMMENT DE MALADIES INFECTIEUSES BACTÉRIENNES. LES NOUVEAUX DÉRIVÉS DE LYSOBACTINE SE DISTINGUENT DE LA SUBSTANCE NATURELLE PAR LA CHAÎNE PEPTIDIQUE N-TERMINALE QUI CONTIENT UN RADICAL 3-(3-PYRIDYL)-ALANYLE.
MA29955A 2004-11-05 2007-05-30 Nonadepsipeptides acyles sous forme de derives de lysobactine MA29218B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004053407A DE102004053407A1 (de) 2004-11-05 2004-11-05 Acylierte Nonadepsipeptide II

Publications (1)

Publication Number Publication Date
MA29218B1 true MA29218B1 (fr) 2008-02-01

Family

ID=35462537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29955A MA29218B1 (fr) 2004-11-05 2007-05-30 Nonadepsipeptides acyles sous forme de derives de lysobactine

Country Status (27)

Country Link
US (1) US7531507B2 (fr)
EP (1) EP1807443A1 (fr)
JP (1) JP4843614B2 (fr)
KR (1) KR20070083984A (fr)
CN (1) CN101056887A (fr)
AR (1) AR053775A1 (fr)
AU (1) AU2005300815B2 (fr)
BR (1) BRPI0516677A (fr)
CA (1) CA2586704A1 (fr)
CR (1) CR9079A (fr)
DE (1) DE102004053407A1 (fr)
GT (1) GT200500308A (fr)
HN (1) HN2005030779A (fr)
IL (1) IL182739A (fr)
MA (1) MA29218B1 (fr)
MX (1) MX2007005382A (fr)
MY (1) MY145448A (fr)
NO (1) NO20072854L (fr)
NZ (1) NZ554813A (fr)
PE (1) PE20060942A1 (fr)
RU (1) RU2414477C2 (fr)
SV (1) SV2006002290A (fr)
TW (1) TW200621799A (fr)
UA (1) UA89800C2 (fr)
UY (1) UY29189A1 (fr)
WO (1) WO2006048139A1 (fr)
ZA (1) ZA200703674B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004051024A1 (de) * 2004-10-20 2006-04-27 Bayer Healthcare Ag Heterocyclyl-substituierte Nonadepsipeptide
DE102004051023A1 (de) * 2004-10-20 2006-05-04 Bayer Healthcare Ag Desoxo-Nonadepsipeptide
DE102004051025A1 (de) * 2004-10-20 2006-04-27 Bayer Healthcare Ag Substituierte Nonadepsipeptide
DE102004053410A1 (de) * 2004-11-05 2006-05-11 Bayer Healthcare Ag Cyclische Nonadepsipeptidamide
DE102006003443A1 (de) * 2006-01-25 2007-07-26 Aicuris Gmbh & Co. Kg Asparagin-10-substituierte Nonadepsipeptide
DE102006018250A1 (de) * 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Verfahren zum Herstellen von cyclischen Depsipeptiden
DE102006018080A1 (de) * 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Lysobactinamide
TW201717991A (zh) * 2015-08-17 2017-06-01 拜耳動物保健有限公司 用於治療牛乳房炎之溶桿菌素
MX389001B (es) * 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
EP3363452A1 (fr) 2017-02-17 2018-08-22 Bayer Animal Health GmbH Combinaisons de lysobactine et d'aminoglycosides contre des maladies provoquées par des bactéries à gram positif et à gram négatif chez des animaux non humains
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1266247C (fr) 1985-03-25 1990-02-27 Antibiotique prepare par lysobacter sp. sc14,067
JPH01132600A (ja) 1987-11-17 1989-05-25 Shionogi & Co Ltd カタノシンａおよびｂならびにその製造法
DE10320781A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag Acylierte Nonadepsipeptide

Also Published As

Publication number Publication date
RU2007120686A (ru) 2008-12-10
PE20060942A1 (es) 2006-10-20
MX2007005382A (es) 2007-08-14
CN101056887A (zh) 2007-10-17
SV2006002290A (es) 2006-10-13
AR053775A1 (es) 2007-05-23
NZ554813A (en) 2009-11-27
CA2586704A1 (fr) 2006-05-11
EP1807443A1 (fr) 2007-07-18
MY145448A (en) 2012-02-15
AU2005300815A1 (en) 2006-05-11
RU2414477C2 (ru) 2011-03-20
BRPI0516677A (pt) 2008-09-16
TW200621799A (en) 2006-07-01
US20060264358A1 (en) 2006-11-23
KR20070083984A (ko) 2007-08-24
ZA200703674B (en) 2008-09-25
UA89800C2 (en) 2010-03-10
JP4843614B2 (ja) 2011-12-21
WO2006048139A1 (fr) 2006-05-11
CR9079A (es) 2007-08-28
IL182739A (en) 2013-03-24
US7531507B2 (en) 2009-05-12
IL182739A0 (en) 2007-07-24
JP2008518982A (ja) 2008-06-05
UY29189A1 (es) 2006-06-30
NO20072854L (no) 2007-08-01
HN2005030779A (es) 2010-08-19
DE102004053407A1 (de) 2006-05-11
GT200500308A (es) 2006-06-02
AU2005300815B2 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
EP1539228A4 (fr) Nouvelles composition et methodes servant au traitement de maladies associees au systeme immunitaire
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
MA30337B1 (fr) Anticorps
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
DE60219887D1 (de) N-(3,-Dimethylindolin-6-yl)ä2-ä(4-pyridylmethyl)aminoü(3-pyridyl)ücarbonsäureamid und dieses enthaltende pharmazeutische Zubereitungen.
TNSN07238A1 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes. pharmaceutical formulations containing the same, and use thereof as medicaments
MA30063B1 (fr) Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg)
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
WO2003103584A3 (fr) Imidazopyridines a substitution ether
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
EP1505990A4 (fr) Methodes de traitement de l'hepatite
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
NO976048L (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
DK2018170T3 (da) Lægemiddel mod brystcancer
MA30039B1 (fr) Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires
TR200002626T2 (tr) Terkip
ES2194677T3 (es) Suspensiones de trovafloxacina de administracion por via oral.
EP1601756A4 (fr) Methodes et compositions de traitement du cancer et de maladies infectieuses utilisant des complexes de molecules antigenes d'alpha (2) macroglobuline
EE200100125A (et) TAN-1057 derivaadid